進行した肺がんにおける症状モニタリングによる患者ナビゲーションのランダム化試験
Kumar Prabhash1, Vanita Noronha1, Vijay Patil2
1Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India.
European journal of cancer (Oxford, England : 1990)
|August 24, 2025
まとめ
症状のモニタリングによる患者ナビゲーションは,治療開始を大幅に早め,進行した肺がん患者の治療順守を改善します. このアプローチは緊急診察を減らしますが,生活の質や生存結果に影響しません.
科学分野:
- 腫瘍学
- 臨床試験
- 患者のケア管理
背景:
- 癌の治療における障壁は 支援的な介入を必要とします
- 忍耐強いナビゲーターは これらの障壁を軽減することができます
- 進行した肺がんの治療における症状モニタリングの役割は評価する必要がある.
研究 の 目的:
- 症状のモニタリングと組み合わせた患者のナビゲーションの影響を評価する.
- 進行した肺がん患者の生活の質 (QoL) とケア提供への影響を評価する.
- 治療開始,順守,生存を含む二次的エンドポイントを分析する.
主な方法:
- 進行した肺がん患者150人を対象としたランダム化比較試験.
- 介入グループは患者ナビゲーション (調整,スケジュール,症状モニタリング) を受けました.
- 主要エンドポイント: 12週間のQOL変化; 副次エンドポイント: 治療までの時間,予定外の訪問,順守,生存.
主要な成果:
- 介入グループでは,治療開始までの時間が著しく短かった (19 vs. 28日).
- 緊急診察や予定外の診察の頻度が減った (67% 対 88%) で,治療順守が向上した (85% 対 68%).
- QoL,パフォーマンスステータス,無進行生存期 (PFS),全生存期 (OS) の有意な差異は認められなかった.
結論:
- 症状のモニタリングによる患者ナビゲーションは 癌の治療の提供を強化します
- 治療開始を早め,従順性を向上させ,計画外の医療利用を減らせる.
- 介入は患者の生活の質や生存に悪影響を及ぼさない.
さらに関連する動画
関連する概念動画
02:43Mouse Models of Cancer Study
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:43Mouse Models of Cancer Study
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...